# EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries

> **NCT01919190** · PHASE4 · TERMINATED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 67 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** EXPAREL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01919190
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2013-12
- **Final completion:** 2014-02
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Due to reasons unrelated to safety; primary endpoint signal seen during pre-specified interim analysis.
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919190, "EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01919190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*